Formosa Pharmaceuticals Investors
Financials
Consolidated Financial Statements
- 2025 Q1 Consolidated Financial Statements
- 2024 Q4 Consolidated Financial Statements
- 2024 Q3 Consolidated Financial Statements
- 2024 Q2 Consolidated Financial Statements
- 2024 Q1 Consolidated Financial Statements
- 2023 Q4 Consolidated Financial Statements
- 2023 Q3 Consolidated Financial Statements
- 2023 Q2 Consolidated Financial Statements
- 2022 Q4 Consolidated Financial Statements
- 2022 Q2 Consolidated Financial Statements
- 2021 Q4 Consolidated Financial Statements
- 2021Q2 Consolidated Financial Statements
- 2020 Consolidated Financial Statements
- 2019 Consolidated Financial Statements
Parent Company Only Financial Statements
News Highlight
Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
2025-12-03
Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – December 3, 2025 –
